CD274 and neoplasm: Targeting the interactions between PD-L1 on the tumor-cell surface and PD-1 on T cells with antibodies has shown great promise for significantly prolonging patient survival in several solid tumors, such as advanced metastatic melanoma, non-small cell lung cancer, and renal cell carcinoma [2].